Stock Market Reviews

CRSP (CRISPR Therapeutics AG) News

Get the latest news, insights, and market updates on CRSP (CRISPR Therapeutics AG). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
  Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
  Nov 21, 2025 - $CRSP
• 3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
  These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.
  Nov 21, 2025 - $CRSP
• This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
  CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.
  Nov 19, 2025 - $CRSP
• Top 3 Genomics Stocks to Consider for Your Portfolio
  Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
  Nov 18, 2025 - $CRSP
• RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform
  CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares. The analysts noted that CASGEVY, CRISPR’s leading product, missed […]
  Nov 18, 2025 - $CRSP
• Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
  Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels and a well-tolerated safety profile, with results presented at the American Heart Association Scientific Sessions and published in The New England Journal of Medicine. The advance of CTX310 into further clinical trials marks important momentum in CRISPR Therapeutics’ pipeline, as lipid disorders...
  Nov 17, 2025 - $CRSP
• 1 Underrated Stock That Could Soar by 58%, According to Wall Street
  This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?
  Nov 17, 2025 - $CRSP
• CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
  Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
  Nov 14, 2025 - $CRSP
• Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks
  On Monday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. (NASDAQ:TSLA), Pony AI Inc. (NASDAQ:PONY), Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM), and Baidu Inc. (NASDAQ:BIDU). These trades highlight Ark’s ...
  Nov 12, 2025 - $CRSP
• Cathie Wood doubles down on Alibaba: ARK Invest snaps up $25M in Chinese tech stocks
  ARK unloads Reddit, adds Alibaba -- Cathie Wood bets on China rebound
  Nov 12, 2025 - $CRSP